Drugs / Izokibep
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03580278 | Nov 2019 → Sep 2020 | psoriasis | Affibody | Completed | No outcome recorded |
| Phase 1 | NCT02690142 | Feb 2016 → Jan 2018 | psoriasis | Affibody | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05384249 | Aug 2022 → Feb 2025 | uveitis | ACELYRIN Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05355805 | May 2022 → Aug 2023 | hidradenitis suppurativa | ACELYRIN Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04706741 | Jan → Aug 2022 | uveitis | ACELYRIN Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04795141 | Aug 2021 → Jul 2022 | ankylosing spondylitis | Inmagene LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04713072 | Aug 2020 → Oct 2021 | psoriatic arthritis | ACELYRIN Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03591887 | Mar 2018 → Mar 2019 | psoriasis | Affibody | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05623345 | Nov 2022 → Nov 2023 | psoriatic arthritis | ACELYRIN Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05905783 | Jun 2023 → Jul 2024 | hidradenitis suppurativa | ACELYRIN Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | izokibep | “In this study, the AffibodyⓇ technology was used to identify and optimize a novel, small, biological molecule comprising three triple helical affinity domains, izokibep...” PMID 37184136 ↗ Jan 2023 |
| Known as | ABY-035 | “In this study, the AffibodyⓇ technology was used to identify and optimize a novel, small, biological molecule comprising three triple helical affinity domains, izokibep...” PMID 37184136 ↗ Jan 2023 |
| Known as | ABY-035/AFO2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03580278 ↗ |
| Known as | IMG-020 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297686 ↗ |
| Action | Inhibit | “for the inhibition of IL-17A signaling.” PMID 37184136 ↗ Jan 2023 |
| Modality | Protein / enzyme biologic | “a small 18.6 kDa IL-17 ligand trap comprising two IL-17A-specific Affibody domains and one albumin-binding domain” PMID 37184136 ↗ Jan 2023 |
| Route | Intravenous | “ABY-035 given as intravenous injections.” NCT02690142 ↗ |
| Target | IL17A | “selectively inhibits human IL-17A in vitro and in vivo” PMID 37184136 ↗ Jan 2023 |